SG11201808849TA - Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative - Google Patents

Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Info

Publication number
SG11201808849TA
SG11201808849TA SG11201808849TA SG11201808849TA SG11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA
Authority
SG
Singapore
Prior art keywords
box
rehovot
international
science
york
Prior art date
Application number
SG11201808849TA
Other languages
English (en)
Inventor
Avigdor Scherz
Yoram Salomon
Liiach Agemy
Rachel Hamri
Dina Preise
Kwanghee Kim
Jonathan Coleman
Original Assignee
Yeda Res & Dev
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Memorial Sloan Kettering Cancer Center filed Critical Yeda Res & Dev
Publication of SG11201808849TA publication Critical patent/SG11201808849TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201808849TA 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative SG11201808849TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Publications (1)

Publication Number Publication Date
SG11201808849TA true SG11201808849TA (en) 2018-11-29

Family

ID=58794130

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808849TA SG11201808849TA (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Country Status (14)

Country Link
US (2) US11278555B2 (cg-RX-API-DMAC7.html)
EP (1) EP3442582A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019510807A (cg-RX-API-DMAC7.html)
KR (2) KR20190008206A (cg-RX-API-DMAC7.html)
CN (2) CN118304400A (cg-RX-API-DMAC7.html)
AU (2) AU2017250732B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018070847A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020067A1 (cg-RX-API-DMAC7.html)
IL (1) IL262191B2 (cg-RX-API-DMAC7.html)
MX (2) MX390751B (cg-RX-API-DMAC7.html)
RU (2) RU2021110230A (cg-RX-API-DMAC7.html)
SG (1) SG11201808849TA (cg-RX-API-DMAC7.html)
WO (1) WO2017179053A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201807187B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
CN106458190B (zh) 2014-05-30 2019-12-06 戴科知识产权控股有限责任公司 具有喷射器、气动控制阀和可选择的吸气器的真空创建系统
WO2019116376A1 (en) * 2017-12-17 2019-06-20 Yeda Research And Development Co. Ltd. Cop9 signalosome (csn) complex modulators and uses thereof
WO2022149934A1 (ko) * 2021-01-08 2022-07-14 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201172B1 (pl) 1998-12-09 2009-03-31 Yeda Res & Dev Pd-Bakteriofeoforbid, sposób jego wytwarzania, kompozycja farmaceutyczna zawierająca go i jego zastosowanie
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
AU2009305893B2 (en) 2008-10-23 2014-03-27 Steba Biotech S.A. RGD-containing peptidomimetics and uses thereof
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
TWI442945B (zh) * 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Also Published As

Publication number Publication date
MX2022003190A (es) 2022-04-11
EP3442582A1 (en) 2019-02-20
BR112018070847A2 (pt) 2019-02-05
RU2747258C2 (ru) 2021-04-29
US20190125769A1 (en) 2019-05-02
MX390751B (es) 2025-03-21
AU2017250732A1 (en) 2018-11-15
JP2022031823A (ja) 2022-02-22
AU2017250732B2 (en) 2022-11-10
IL262191B2 (en) 2025-01-01
KR20190008206A (ko) 2019-01-23
IL262191A (en) 2018-11-29
IL262191B1 (en) 2024-09-01
CA3020067A1 (en) 2017-10-19
AU2023200591A1 (en) 2023-03-09
US20220202838A1 (en) 2022-06-30
JP2019510807A (ja) 2019-04-18
CN109862918A (zh) 2019-06-07
WO2017179053A1 (en) 2017-10-19
ZA201807187B (en) 2020-01-29
CN118304400A (zh) 2024-07-09
RU2018139523A (ru) 2020-05-15
RU2021110230A (ru) 2021-05-26
US11278555B2 (en) 2022-03-22
RU2018139523A3 (cg-RX-API-DMAC7.html) 2020-07-07
MX2018012392A (es) 2019-08-21
KR20220139445A (ko) 2022-10-14

Similar Documents

Publication Publication Date Title
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201811225RA (en) Ar+ breast cancer treatment methods
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201810162PA (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201908391XA (en) Methods for modulating an immune response
SG11201903946SA (en) Devices and methods for slurry generation
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201810440VA (en) Medical devices, systems and methods utilizing permanent magnet and magnetizable feature
SG11201810951RA (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201808306PA (en) Treatment of cancer with tg02
SG11201811237WA (en) Combination therapies
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201900132QA (en) Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer